CYP1A1 and lung cancer: They reported that the pooled ORs for CYP1A1 Ile462Val heterozygote and homozygote polymorphisms were 1.15 (95% CI 0.95–1.39) and 1.54 (95% CI 0.97–1.46), respectively, and that the CYP1A1 Ile462Val polymorphism may confer an increased risk of lung cancer in women (OR 2.70, 95% CI 1.79–4.08 vs. OR 1.08, 95% CI 0.88–1.32 in men) [23].